硼中子俘获疗法（BNCT）中硼载体硼代苯丙氨酸（BPA）和/或十氢十硼酸酯（GB-10）在肺转移实验模型中的生物分布。
Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases.
作者信息
Trivillin V A, Garabalino M A, Colombo L L, González S J, Farías R O, Monti Hughes A, Pozzi E C C, Bortolussi S, Altieri S, Itoiz M E, Aromando R F, Nigg D W, Schwint A E
机构信息
National Atomic Energy Commission, Argentina; National Research Council (CONICET), Argentina.
National Atomic Energy Commission, Argentina.
出版信息
Appl Radiat Isot. 2014 Jun;88:94-8. doi: 10.1016/j.apradiso.2013.11.115. Epub 2013 Dec 5.
BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25-76ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.
硼中子俘获疗法（BNCT）被提议用于治疗肺部弥漫性、不可切除的肿瘤。我们在大鼠播散性肺转移的实验模型中，采用5种给药方案，使用硼载体双对氨基苯甲醚（BPA）和/或GB-10进行了硼生物分布研究。所有5种方案均无毒，且与肺相比，肿瘤对硼的摄取具有优先性。对于3种方案，绝对肿瘤硼浓度值在治疗上是有用的（25 - 76ppm）。剂量学计算表明，在不超过肺的放射耐受性的情况下，在RA-3进行BNCT可能具有治疗作用。
Zotero 插件